We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Maxcyte Inc | MXCT | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 295.00 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 295.00 | 295.00 | 295.00 | 295.00 | 295.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 05/3/2024 08:59 by adamb1978 Not sure Dave. THe core revenue growth figure is underwhelming - new licenses are meant to tranlsate into incremental revenues...wonder whether:- any licensees have terminated? - any have asked for restructured/written off payments due to funding problems? - MXCT have changed commercial structures? |
Posted at 30/1/2024 16:38 by mysteronz These SPL signings are really starting to grow now.Maybe a sign of increased confidence in bio investment or the MXCT platform, either way future money in the bank/sign on fee :) |
Posted at 11/12/2023 23:47 by davep4 Duplicate post. |
Posted at 11/12/2023 23:47 by davep4 Doug Doerfler, will retire as President and Chief Executive Officer, effective January 1, 2024.…. the company now expects to exceed prior SPL program-related guidance, with revenue of at least $10 million. |
Posted at 11/12/2023 08:51 by pob69 Also curious to see that this research provider appears to no longer cover MXCT. Their last note was 9/22 entitled "Vertex Pharmaceuticals secures exa-cel SPL". They are not the house broker though.This note offers the most commentary on exa-cel |
Posted at 11/12/2023 08:19 by adamb1978 Thanks Junior. Was expecting an RNS from MXCT this morning. The fee for them generated from the vertex approval is probably close to being a 'material' event relative to mkt expectations for revenue. Add in the future royalties, I think its certainly RNS-able |
Posted at 01/11/2023 09:20 by 74tom Some interesting comments on this old seeking alpha article;"Another important point on the competitive position is the potential long-term customer lock-in that MXCT can achieve, on top of the long-term partnership agreements. If a therapy gets FDA approval using MXCT's tech, that would be considered a critical supplier, I expect it will be very difficult to switch after approval (long and uncertain validation process to prove bio-equivalence, etc). However, you don't mention anything on MXCT's IP. Is their technology well protected and what's the remaining life of their patents?" "I agree that there is no sense in switching to another service provider once a therapy is FDA approved using MaxCyte's technology. In terms of IP there is quite a lot of information in the Prospectus. I will just copy an extract here: "As of May 4, 2021, we have 50 granted U.S. and foreign patents, including in foreign 109 jurisdictions such as Australia, Canada, Japan, China, South Korea and certain countries in Europe, as well as 76 pending patent applications worldwide. The main focus of our patent coverage protects our Flow Electroporation, processing chambers/disposables That's very impressive on the patent front... |
Posted at 01/11/2023 08:53 by adamb1978 Over 100% of MXCT average daily volume traded, and its not 9am yet |
Posted at 01/11/2023 08:21 by 74tom Fantastic FDA adcomm yesterday, well worth listening to the full 7 hours when time permits;The final hour was especially positive, approval looks highly likely based on the panel discussion & the fact that there seemed to be unanimous agreement that the significant patient benefits of exa-cel comprehensively outweigh the risks of off target edits. The whole sector received a boost yesterday, enhanced by Eli Lilly entering the gene editing space via purchasing a Verve Therapeutics license from Beam for $250m. I strongly suspect the bottom is in & MXCT could see a rapid recovery over the next few of months as both CRISPR indications receive approval. |
Posted at 31/10/2023 08:05 by adamb1978 Thanks Sebass. That's very helpful - thank you. Is that vote typically made public?Hopefully MXCT would RNS it if positive |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
